Haemonetics Acquires Vivasure Medical for €185M: Bioabsorbable Patch Technology Disrupts Large-Bore Vascular Closure
Haemonetics acquired Ireland-based Vivasure Medical for up to €185 million, adding the PerQseal Elite bioabsorbable vascular closure system to its interventional technologies portfolio. This guide covers the sutureless patch-based closure technology for large-bore arteriotomies up to 26F, ELITE clinical study results showing 0% major complications at 30 days, the PMA regulatory pathway submitted to FDA in June 2025, CE Mark approval for arterial and venous indications, and the competitive landscape in structural heart and endovascular closure devices including Abbott's Perclose ProGlide and Medtronic's Angio-Seal.
The Deal at a Glance
On January 9, 2026, Haemonetics Corporation (NYSE: HAE) completed its acquisition of Vivasure Medical Limited, a Galway, Ireland-based company pioneering fully absorbable technology for percutaneous vessel closure. The deal brings the PerQseal Elite vascular closure system — the first and only 100% bioabsorbable, sutureless, patch-based closure device on the market — into Haemonetics' growing interventional technologies portfolio.
| Detail | Information |
|---|---|
| Acquirer | Haemonetics Corporation (NYSE: HAE) |
| Target | Vivasure Medical Limited |
| Deal Type | Cash acquisition (existing strategic investor) |
| Announced / Closed | January 9, 2026 |
| Upfront Cash Payment | €100 million (~$116.4 million) |
| Net Upfront (after prior investments/loans) | |
| Contingent Consideration | Up to €85 million (~$99 million) based on sales growth and milestones |
| Total Potential Deal Value | Up to €185 million (~$216 million) |
| Financing | Cash on hand |
| Target HQ | Galway, Ireland |
| Target CEO | Andrew Glass |
| Key Asset | PerQseal Elite vascular closure system |
| CE Mark Status | Arterial (April 2025) and venous (June 2025) |
| FDA Status | PMA submitted June 2025 (arterial indication); not yet approved |
| Estimated Large-Bore Closure TAM | ~$300 million (per Haemonetics) |
The deal structure is notable for Haemonetics' pre-existing relationship with Vivasure. Haemonetics made a strategic investment in Vivasure in 2022 that included an option to acquire the company. After Vivasure hit key clinical and regulatory milestones — including CE Mark approval and PMA submission — Haemonetics triggered the option. The net upfront payment of approximately €52 million reflects the subtraction of prior investments and loans already extended, meaning Haemonetics' incremental cash outlay at closing was significantly lower than the headline €100 million figure.
The Players
Haemonetics Corporation
Haemonetics is a global medical technology company headquartered in Boston, Massachusetts, focused on delivering innovative solutions to improve patient outcomes across three primary business segments: hospital technologies, plasma collection, and blood center solutions. The company is publicly traded on the New York Stock Exchange (HAE) and generated approximately $1.3 billion in revenue in fiscal year 2025.
Within its hospital portfolio, Haemonetics has been building an interventional technologies business focused on vascular access and closure. This portfolio includes the VASCADE family of vascular closure systems — VASCADE (small-bore, 5-7F), VASCADE MVP (mid-bore venous, 6-12F), and VASCADE MVP XL (mid-bore venous, 10-15F). These devices use a collapsible disc technology with a resorbable collagen patch.
The Vivasure acquisition extends Haemonetics' closure portfolio into the large-bore segment (14-22F sheaths, up to 26F outer diameter), addressing procedures like TAVR, EVAR, and TMVR where current closure options are limited.
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, stated: "Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures. With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals."
Vivasure Medical Limited
Vivasure Medical was founded in Galway, Ireland to develop next-generation percutaneous vessel closure technology. The company operates an integrated R&D and ISO 13485-certified manufacturing facility in Galway, giving it control over both design and production of its bioabsorbable implants and delivery systems.
Under CEO Andrew Glass, Vivasure advanced the PerQseal platform through a series of clinical studies — from first-in-human through the U.S. pivotal PATCH study and the European ELITE studies — while securing CE Mark approval and submitting a PMA to the FDA. Glass's background spans equity investments at Abbott Ventures and commercial roles in medical device sales, providing a blend of clinical, commercial, and investment perspective that guided the company through its strategic exit.
Vivasure's investors included Fountain Healthcare Partners, Orchestra BioMed Holdings, LSP Health Economics Fund (managed by EQT Life Sciences), Panakes Partners, and Evonik Venture Capital, with support from Enterprise Ireland, the Western Development Commission, and the European Investment Bank.
Andrew Glass commented on the acquisition: "Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide."
The Clinical Problem: Large-Bore Vessel Closure
Why Large-Bore Closure Is Hard
Structural heart and endovascular procedures require large-bore access — catheters and delivery systems ranging from 14 French to 22 French in sheath size, creating arteriotomies up to 26F in outer diameter. A 22F sheath creates a puncture site roughly 7-8 millimeters wide in the common femoral artery. Closing that hole reliably, without complications, is one of the most technically demanding steps in these procedures.
The common femoral artery is the preferred access site for most large-bore cardiovascular procedures due to its size, accessibility, and relatively straightforward percutaneous approach. However, the vessel must be sealed effectively to prevent life-threatening bleeding complications including hematoma, retroperitoneal hemorrhage, pseudoaneurysm, and arteriovenous fistula.
Current Approaches and Their Limitations
Before examining PerQseal Elite's technology, it is important to understand what clinicians currently face:
Suture-Based Closure (e.g., Abbott Perclose ProGlide): This approach uses suture-mediated devices to stitch the arteriotomy closed. For large-bore access, the "pre-close" technique is typically required — the operator deploys two ProGlide devices in a specific configuration before the large sheath is inserted, then tightens the sutures after the procedure. This adds procedural steps, requires specialized training, and has a measurable learning curve. Vascular complications rates with suture-based closure in TAVR have been reported in the range of 10-21% in various studies, though rates have improved with newer techniques and operator experience.
Collagen-Based Closure (e.g., Teleflex MANTA): The MANTA device uses a collagen-based implant with a toggle-and-suture mechanism to seal the arteriotomy. It was the first FDA-approved device specifically designed for large-bore vascular closure (approved February 2019 under PMA P180025). MANTA does not require pre-close technique, simplifying the workflow. However, it leaves permanent materials in the patient (titanium toggle, collagen, suture). Clinical studies have shown MANTA achieves lower bleeding and complication rates compared to ProGlide in propensity-matched comparisons.
Surgical Cut-Down: For patients where percutaneous closure is not feasible or fails, surgical exposure and direct suture repair of the artery remains the fallback. This adds procedural time, increases infection risk, extends hospital stay, and defeats the purpose of a minimally invasive approach.
The Unmet Need
No existing closure device is fully bioabsorbable. All leave some permanent material behind — sutures, collagen plugs, metal toggles, or clips. Additionally, no existing device is specifically designed and approved for both arterial and venous large-bore closure. As structural heart procedures expand beyond TAVR into transcatheter mitral valve repair/replacement (TMVR), transcatheter tricuspid interventions (TTVR), and leadless pacemaker implants, large-bore venous access is becoming increasingly common, yet dedicated venous closure options are scarce.
PerQseal Elite Technology Deep Dive
Device Architecture
The PerQseal Elite vascular closure system is a single-use device consisting of a bioabsorbable implant, a delivery system, a dedicated introducer sheath, and associated packaging. The implant itself has four key components:
1. Intra-Arterial Scaffold: A low-profile, fully synthetic absorbable structure deployed inside the vessel. The scaffold provides the initial mechanical framework to appose the arteriotomy edges and create a seal from within.
2. Bioabsorbable Patch: The patch is the primary sealing element. Positioned against the inner wall of the vessel at the puncture site, it promotes hemostasis through direct apposition. The patch has an ultra-low profile and is designed for rapid endothelialization — the body's natural healing process covers the patch surface with a layer of endothelial cells, sealing the site biologically as well as mechanically.
3. External Fixation Component: An extra-arterial element that sits on the outside of the vessel wall, enhancing compression of the implant against the arteriotomy. This dual-sided compression — from inside and outside the vessel — is a key differentiator. By sandwiching the vessel wall between the intra-arterial patch and the external fixation, the device achieves a more robust and reliable seal.
4. Bioabsorbable Pin: A securing element that locks the implant components in position during the critical early healing period.
How It Works: Step-by-Step
Procedure completion: After the primary cardiovascular or endovascular procedure is finished, the large-bore procedural sheath remains in the common femoral artery.
Sheath exchange: The procedural sheath is exchanged over a 0.035-inch guidewire for the dedicated PerQseal Elite introducer sheath. The safety guidewire remains in place throughout the closure process, maintaining vessel access in case of device failure.
Device deployment: The PerQseal Elite delivery device is inserted through the introducer sheath. Deployment is automatic and intuitive, with minimal steps required. The bioabsorbable implant is delivered to the puncture site from inside the vessel.
Sealing: The implant is released, with the intra-arterial scaffold and patch positioned against the inner vessel wall and the external fixation component deployed on the outside. The pin secures the assembly. Hemostasis is achieved through the combined mechanical compression and the patch's hemostatic properties.
Absorption: Over approximately 180 days, the fully synthetic implant is completely absorbed by the body. Pre-clinical data demonstrates that the vessel returns to its natural state with no residual foreign material — no collagen, no metal, no sutures remain.
Key Differentiating Features
| Feature | PerQseal Elite | Abbott Perclose ProGlide | Teleflex MANTA |
|---|---|---|---|
| Mechanism | Bioabsorbable patch | Suture-mediated | Collagen-based with toggle |
| Pre-close required | No | Yes (two devices) | No |
| Permanent implant | None — fully absorbed | Sutures remain | Toggle, collagen, suture remain |
| Arterial and venous | Both (CE Mark for both) | Primarily arterial | Arterial only |
| Sheath compatibility | 14-22F (up to 26F OD) | 5-21F (pre-close for >8F) | 12-25F OD |
| Guidewire compatible | 0.035-inch | Varies | Yes |
| Vessel state post-absorption | Returns to natural state | Suture material persists | Collagen and toggle persist |
| Devices per closure | One | Two (for large-bore pre-close) | One |
| Absorption timeline | ~180 days | N/A (permanent) | N/A (permanent) |
The absence of a pre-close requirement is clinically significant. Pre-close technique adds time, complexity, and risk to the procedure — if the primary procedure encounters complications and the case is aborted, the pre-deployed sutures may have already been placed unnecessarily. PerQseal Elite's over-the-wire delivery at the end of the procedure, with no pre-procedural steps, simplifies workflow and reduces the cognitive burden on the operator.
Clinical Evidence
The clinical evidence supporting PerQseal Elite spans two major study programs: the PATCH pivotal study (U.S. IDE) and the ELITE study (European).
PATCH Pivotal Study
The PATCH study was a multicenter, single-arm pivotal study conducted under an investigational device exemption (IDE) in the United States and Europe. It enrolled over 145 patients across 17 investigational sites, evaluating the PerQseal closure device for hemostasis of common femoral arteriotomies created by 12-22F sheaths (up to 26F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
Principal investigators included William A. Gray, MD (Main Line Health / Lankenau Heart Institute, Philadelphia) and Sean Lyden, MD (Cleveland Clinic).
Results presented at TCT 2024 (Transcatheter Cardiovascular Therapeutics, October 2024) showed:
| Endpoint | Result |
|---|---|
| VARC-3 Major Complication Rate (at discharge) | 0.8% in the primary ITT analysis (124 patients) |
| Median Time to Hemostasis | 0 minutes |
| Patients Enrolled | 145+ across 17 sites |
A 0.8% VARC-3 major complication rate is impressively low for large-bore closure, and a median hemostasis time of zero minutes means that for the majority of patients, bleeding stopped immediately upon device deployment. These results formed the clinical basis for the PMA submission to the FDA.
ELITE Arterial Study
The ELITE (Evaluation of Large-bore Iterative Technology for vessel closure Excellence) arterial study is a prospective, single-arm, multicenter study evaluating the PerQseal Elite device specifically (the next-generation iteration of the PerQseal platform).
Results reported by Prof. Nicolas Van Mieghem (Erasmus Medical Centre, Rotterdam) showed:
| Endpoint | Result |
|---|---|
| Major Vascular Complications at 30 Days | 0% |
| Minor Access Site Complications | 2 (requiring manual compression only) |
| Ease of Use | Demonstrated — no preclose technique needed |
| Median Time to Hemostasis | Immediate |
The 0% major complication rate at 30-day follow-up is a striking result, though it should be interpreted in the context of a single-arm study design with selected patients. The results are nonetheless encouraging, particularly the absence of major bleeding events, surgical interventions, or stent-graft placements attributable to the device.
ELITE Venous Study
Vivasure also initiated the ELITE Venous Clinical Study, a prospective, multicenter, single-arm study evaluating PerQseal Elite for closure of common femoral venotomies created by 14-22F sheaths (up to 26F). The first venous patient was treated by Prof. Nicolas Van Mieghem at Erasmus Medical Centre in April 2024. The study planned to enroll up to 97 patients at up to 12 European investigational sites.
This study targets procedures including transcatheter mitral valve repair/replacement (TMVR), transcatheter tricuspid valve repair/replacement (TTVR), leadless pacemaker implants, and other large-bore venous interventions — procedures where no dedicated sutureless closure device previously existed.
As Prof. Van Mieghem noted: "Current venous closure methods are not indicated for large hole venous access applications like TEER, TMVR, and TTVR. As these procedures become more common, there's a need for closure options that can effectively address these emerging clinical applications."
Regulatory Pathway: PMA Submission to FDA
Why PMA and Not 510(k)?
Vascular closure devices for large-bore arteriotomies are classified as Class III medical devices by the FDA, requiring Premarket Approval (PMA) — the most stringent type of device marketing application. Unlike the 510(k) pathway, which demonstrates substantial equivalence to a predicate device, PMA requires affirmative evidence of safety and effectiveness, typically generated through a prospective clinical trial conducted under an IDE.
The PMA pathway was chosen (and required) for PerQseal Elite because:
- No predicate device exists that is substantially equivalent in design (fully bioabsorbable, patch-based, sutureless)
- The device is intended for a high-risk application (large-bore arterial and venous closure)
- Clinical evidence of safety and effectiveness is required beyond bench testing alone
PMA Timeline and Process
Vivasure submitted its PMA application to the FDA in June 2025 for the arterial indication. The submission was built on the PATCH study data (presented at TCT 2024) and positive clinical experience in Europe.
| PMA Milestone | Status |
|---|---|
| IDE Approval for PATCH Study | Granted |
| PATCH Study Patient Enrollment Complete | 145+ patients |
| PATCH Results Presented at TCT 2024 | Positive |
| PMA Submission to FDA | June 2025 |
| FDA Acceptance Review | Expected within 180 days of submission |
| FDA Decision Timeline | 180-320 days from acceptance |
| Advisory Panel Meeting | Possible, at FDA discretion |
Key endpoints that the FDA evaluates for vascular closure device PMAs include:
- Primary safety: Rate of major access site complications (VARC-3 defined), including access-site-related bleeding requiring transfusion, device-related vascular injury requiring surgical repair or stent-graft, and other major vascular events
- Primary effectiveness: Time to hemostasis, device technical success rate, and treatment success rate
- Follow-up: Typically 30-day primary endpoint with 180-day follow-up to assess absorption and long-term vessel patency
The PATCH study's 0.8% VARC-3 major complication rate and median zero-minute hemostasis time compare favorably with historical benchmarks for large-bore closure devices. The MANTA device, for example, received FDA PMA approval in February 2019 based on data showing a major vascular complication rate of approximately 4% at 30 days.
CE Mark Pathway
In Europe, Vivasure pursued and obtained CE Marking under the EU MDR through a more modular approach:
- April 2025: CE Mark received for the arterial indication, covering closure of large-bore arteriotomies following procedures such as TAVR and EVAR
- June 2025: CE Mark expanded to include the venous indication — large-bore venous closure following TMVR, TTVR, leadless pacemaker implants, and other venous procedures
The dual arterial-venous CE Mark positions PerQseal Elite as the first fully bioresorbable, sutureless solution approved for both access types. Vivasure planned to launch PerQseal Elite in select European markets in Summer 2025.
Haemonetics' Interventional Technologies Portfolio
The Vivasure acquisition is the latest in a series of strategic moves by Haemonetics to build a comprehensive vascular closure franchise:
| Product | Segment | Sheath Size | Indication | Status |
|---|---|---|---|---|
| VASCADE | Small-bore arterial/venous | 5-7F | Diagnostic and interventional catheterization | FDA cleared |
| VASCADE MVP | Mid-bore venous | 6-12F | Multi-access electrophysiology and interventional | FDA cleared |
| VASCADE MVP XL | Mid-bore venous | 10-15F | LAAC, AFib ablation, multi-access EP | FDA approved |
| PerQseal Elite | Large-bore arterial and venous | 14-22F (up to 26F OD) | TAVR, EVAR, TMVR, TTVR | CE Mark; PMA pending at FDA |
| OptoWire | Pressure guidewire | N/A | FFR/iFR physiologic assessment | Available |
Prior acquisitions in the interventional space include Cardiva Medical (the VASCADE platform) and OpSens (fiber-optic pressure sensor technology for the OptoWire). The Vivasure deal fills a clear gap in the portfolio — large-bore arterial closure — while also adding a unique venous closure capability for the largest sheath sizes.
Haemonetics estimates the total addressable market for large-bore closure at approximately $300 million, according to Needham analyst Mike Matson. With Teleflex's MANTA currently positioned as the primary FDA-approved dedicated large-bore closure device in the U.S. market, Haemonetics is positioning PerQseal Elite as a differentiated, next-generation alternative pending FDA approval.
Competitive Landscape in Vascular Closure
The vascular closure device market is moderately consolidated, with Abbott, Terumo, Cardinal Health, Teleflex, and Haemonetics collectively accounting for roughly 79% of the global market. Abbott holds the largest share at approximately 37% as of 2024, driven primarily by the Perclose ProGlide and StarClose SE platforms.
Large-Bore Closure: The Competitive Battleground
| Competitor | Device | Mechanism | Large-Bore (12F+) | Arterial | Venous | Permanent Implant | FDA Status |
|---|---|---|---|---|---|---|---|
| Abbott | Perclose ProGlide | Suture-mediated | Yes (pre-close) | Yes | Limited | Yes (sutures) | FDA cleared |
| Teleflex | MANTA | Collagen + toggle | Yes (12-25F OD) | Yes | No | Yes (titanium toggle, collagen, suture) | PMA approved (2019) |
| Cordis | MYNX CONTROL | PEG sealant | Expanding | Yes | Yes (venous FDA approved 2024) | No (PEG sealant is resorbed) | FDA cleared |
| Haemonetics/Vivasure | PerQseal Elite | Bioabsorbable patch | Yes (14-22F, up to 26F OD) | Yes | Yes | No — fully absorbed | PMA submitted (arterial); CE Mark (both) |
| Medtronic | Angio-Seal | Collagen plug + suture anchor | No (5-8F primarily) | Yes | No | Yes (collagen, suture anchor) | FDA cleared |
| Terumo | Angio-Seal (distributed) | Collagen plug + suture anchor | No (5-8F primarily) | Yes | No | Yes | FDA cleared |
The large-bore segment is where competitive intensity is highest because the market is growing rapidly (driven by TAVR and EVAR volume expansion) and because existing solutions have meaningful limitations. Key competitive dynamics:
Abbott Perclose ProGlide remains the market leader by volume but requires pre-close technique for large-bore procedures, which adds complexity and has a learning curve. Studies comparing ProGlide to MANTA in TAVR patients have shown higher bleeding rates and longer hospital stays with ProGlide.
Teleflex MANTA simplified large-bore closure by eliminating the pre-close requirement but leaves permanent material in the patient. Teleflex further strengthened its vascular intervention portfolio by entering a definitive agreement to acquire Biotronik's Vascular Intervention business in February 2025.
Cordis MYNX CONTROL uses a polyethylene glycol (PEG) sealant that is resorbed, addressing the permanence issue. Cordis received FDA approval for the venous indication in July 2024 and secured a national agreement with Premier, Inc., expanding commercial reach.
Haemonetics/Vivasure PerQseal Elite is differentiated by being the only fully bioabsorbable, sutureless, patch-based device. Its dual arterial-venous capability (CE Mark for both) is unique. The key question is the FDA timeline — if approved, it would offer U.S. physicians a closure option that leaves no permanent material behind.
Market Drivers: Growth in TAVR, TMVR, and Endovascular Procedures
The demand for large-bore vascular closure is growing on multiple fronts:
TAVR Volume Expansion
The global TAVR market was valued at approximately $7.2-12 billion in 2025 (depending on the research source) and is projected to grow at a CAGR of 6.4-7% through 2035. Edwards Lifesciences alone reported TAVR sales of $1.2 billion in Q1 2026, a 14.4% year-over-year increase, and raised its full-year guidance. Over 1.5 million cardiac catheterization procedures are performed annually in the United States alone.
TAVR has become the standard of care for severe aortic stenosis across all surgical risk categories, and expansion into moderate and even low-risk patients continues to drive volume growth. Each TAVR procedure requires large-bore femoral arterial access (typically 14-20F sheaths), creating a one-to-one demand relationship between TAVR volume and large-bore closure need.
TMVR and Tricuspid Interventions
Transcatheter mitral valve repair and replacement (TMVR) and transcatheter tricuspid valve repair and replacement (TTVR) are earlier in their adoption curve but represent a growing source of both large-bore arterial and venous access needs. TMVR procedures often require large-bore venous access (up to 24F), a segment where PerQseal Elite's CE Mark for venous closure is directly relevant.
EVAR and TEVAR
Endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR) require large-bore arterial access (typically 16-24F sheaths). As endovascular techniques replace open surgical repair for abdominal and thoracic aortic aneurysms, procedure volumes continue to grow, creating additional demand for reliable large-bore closure.
Vascular Closure Device Market
The global vascular closure device market was valued at approximately $1.7-1.9 billion in 2025 and is projected to reach $2.5-4.1 billion by 2033-2035, growing at a CAGR of 5.7-7.9%. Within this market, the large-bore segment is the fastest-growing sub-category, driven by the procedure volume trends described above.
The broader shift toward outpatient and same-day discharge for interventional procedures is also accelerating VCD adoption. Effective closure is a prerequisite for early ambulation and same-day discharge — if the access site is not sealed reliably, patients cannot be safely discharged. CMS reimbursement codes (CPT 37191 and 37192) provide approximately $2,553 and $1,716 respectively, supporting the economic case for dedicated closure devices.
Implications for Cardiovascular Device Regulatory Strategy
The Vivasure acquisition illustrates several broader themes in cardiovascular device regulatory strategy that are relevant beyond this single transaction.
The PMA Investment Thesis
Developing a novel Class III cardiovascular device through the PMA pathway requires significant capital, time, and clinical infrastructure. Vivasure's journey — from first-in-human studies through a multinational pivotal trial (PATCH) to PMA submission — took multiple years and tens of millions of dollars in investment. The total raised from venture investors and strategic partners was substantial.
This is precisely why acquisition by a larger company with commercial infrastructure is often the optimal exit strategy for companies pursuing PMA-path devices. The acquiring company provides:
- Established sales force relationships with interventional cardiologists and vascular surgeons
- Hospital contracting and GPO access
- Regulatory affairs infrastructure for post-approval studies and labeling changes
- Manufacturing scale-up capabilities
- Financial resources to support commercial launch investment
Dual Regulatory Strategy: CE Mark First, Then PMA
Vivasure employed a deliberate "Europe first" strategy that is common for novel cardiovascular devices. CE Mark approval (April 2025 for arterial, June 2025 for venous) was obtained ahead of the FDA PMA process, enabling early clinical adoption and revenue generation in Europe while the U.S. regulatory pathway progressed in parallel.
This approach offers several advantages:
- Clinical feedback loop: Real-world European clinical experience provides additional data and physician feedback that can strengthen the PMA application and refine the device
- Revenue generation: European commercial launch can generate revenue to offset ongoing U.S. regulatory costs
- Investor confidence: CE Mark approval de-risks the regulatory story for potential acquirers
- Parallel evidence generation: The European ELITE studies complement the U.S. PATCH study, creating a broader clinical evidence base
Regulatory Milestones as Acquisition Triggers
Haemonetics' 2022 strategic investment with an option to acquire is a structure that aligns the interests of both parties. The investor gets a preferential acquisition price and early access to due diligence, while the startup gets capital and validation. The acquisition option is typically triggered by predefined milestones — in Vivasure's case, the CE Mark approval and PMA submission appear to have been the triggers.
This model is increasingly common in medtech M&A and reflects a broader trend: large strategics are making earlier, smaller bets through option structures rather than waiting for companies to reach full commercial maturity and then paying premium multiples.
Implications for the Large-Bore Closure PMA Pathway
If PerQseal Elite receives FDA approval, it would be only the second device specifically approved for large-bore vascular closure in the United States (after MANTA in 2019). Each new PMA approval in a category establishes benchmarks for future applicants, and the FDA's expectations for clinical evidence tend to evolve as more data becomes available.
The PATCH study's rigorous design — prospective, multicenter, with independent clinical events committee adjudication and VARC-3 defined endpoints — represents the current standard for vascular closure device clinical evidence. Future applicants in the large-bore closure space will likely need to meet or exceed this evidentiary bar.
Looking Forward
The Haemonetics-Vivasure transaction reflects a maturing large-bore vascular closure market that is transitioning from a one-device landscape (MANTA) to a competitive multi-product category. With PerQseal Elite's PMA under review at FDA, Cordis expanding its venous closure franchise, and Teleflex building a combined closure-and-intervention portfolio through the Biotronik acquisition, the competitive dynamics in 2026-2027 will be shaped by which devices achieve FDA approval and how quickly physicians adopt bioabsorbable technology over established suture- and collagen-based approaches.
For Haemonetics, the bet is straightforward: that clinicians and hospital systems will prefer a closure device that works simply (no pre-close), works completely (arterial and venous), and leaves nothing behind. The €185 million question is whether the clinical data and commercial execution will validate that thesis when PerQseal Elite reaches the U.S. market.